Skip to main content
Epidemiology and Health logoLink to Epidemiology and Health
. 2014 Sep 25;36:e2014019. doi: 10.4178/epih/e2014019

Meta-epidemiology

Jong-Myon Bae 1,
PMCID: PMC4220603  PMID: 25266419

Abstract

The concept of meta-epidemiology has been introduced with considering the methodological limitations of systematic review for intervention trials. The paradigm of meta-epidemiology has shifted from a statistical method into a new methodology to close gaps between evidence and practice. Main interest of meta-epidemiology is to control potential biases in previous quantitative systematic reviews and draw appropriate evidences for establishing evidence-base guidelines. Nowadays, the network meta-epidemiology was suggested in order to overcome some limitations of meta-epidemiology. To activate meta-epidemiologic studies, implementation of tools for risk of bias and reporting guidelines such as the Consolidated Standards for Reporting Trials (CONSORT) should be done.

Keywords: Review literature as topic, Meta-analysis as topic, Bias, Epidemiology

INTRODUCTION

To establish the best decision-making processes in healthcare service, new fields of study including evidence-based medicine, evidence-based guidelines, and evidence-based health policy have emerged [1]. In addition, for academic cultivation, a new research methodology called systematic reviews (SR) was proposed, under which, the existing generated evidences are systematically collected and evaluated for synthesis into more valid and useful evidence [2-5].

In particular, the success of SR methodology in resolving the controversy over administering beta-blockers in myocardial infarction patients [6] has firmly established its use in published original articles (OA) related to randomized-controlled clinical trials (RCTs) investigating the efficacy of new medicinal or procedural interventions [7,8].

However, given the fact that the subject of SR is OA, some arguments have shown that, even in the development stage, SR methodology cannot overcome inherent limitations of OAs [4, 9-13]. Noble [5] summarized existing suggestions about the advantages and disadvantages of SRs. As one of the breakthroughs for overcoming these limitations, a new terminology, meta-epidemiology, was introduced [14]. In light of this trend, this study aimed to investigate the background of emergence, definition, purposes and research outcomes from its practical applications of meta-epidemiology.

INTRODUCTION TO META-EPIDEMIOLOGY

Emerging background of meta-epidemiology

While studies using SR methodology were being actively published, some of these studies with the same research hypotheses began to yield conflicting results; moreover, additional problems were identified in the SR reasoning owing to critical limitations inherent in the OA itself [15-19]. Problems associated with errors that can occur while performing the SR research process, include heterogeneity [20,21], publication bias [9,22-24], and outcome reporting bias [25-27], among others; however, studies have shown that fundamental problems in the methodology associated with conducting RCT research, such as allocation concealment or post-allocation patient blinding, made it difficult to provide a rationale for SR results [18,28-35].

On the basis of these findings, attempts have been made to evaluate the quality of the OA more strictly when conducting a SR and to apply the meta-analysis upon appraising the results of specific items [30,36-39]. In particular, as concept separation and establishment for allocation concealment and post-allocation blinding took place, entering the year 2000 [40,41], a serious movement was seen to confirm the validity of study results from SRs on RCT studies that did not reflect these in the research plan [18,27,30,37,42-45]. With this background, diverse methods, such as mega-regression [4,46-48], imputation [15], informative missing odds ratio [26,49], two statistical models [33], and others were attempted and the term “meta-epidemiology” was introduced [14,16,36,50].

Definition and purpose of meta-epidemiology

According to Zhang [14], the term “meta-epidemiology” first appeared in published literature in 1997, in an editorial review by Naylor [50]. In 2002, Sterne et al. [16] attempted to make its meaning more explicit by referring to it as a “statistical method” for examining the influence of qualitative problems in RCTs. However, it is now in the process of being recognized as another epidemiological research methodology that controls meta-confounders, similar to traditional epidemiological research methodology that controls confounding variables [14,30,51]. Here, the difference from traditional epidemiology is that the subjects of traditional epidemiological studies are individuals, whereas those of meta-epidemiological studies are OAs that published the results of RCTs performed.

Thus, meta-epidemiology is based on the combination of two concepts: epidemiology and meta-analysis. To fit the purposes of these two concepts, meta-epidemiology strives to achieve the following: (1) to describe the distribution of research evidence for a specific question; (2) to examine heterogeneity and associated risk factors; and (3) to control bias across studies and summarize research evidence as appropriate [14].

Meta-epidemiology in the literature

Journals that have been published to date with the word “meta-epidemiology” in the journal title or research methodology section have been organized by year as shown in the Appendix 1. Published results with earnest applications of meta-epidemiology are seen after 2008, whereas initial studies were performed to control the influence of allocation concealment and post-allocation blinding [30,32]. As an example, Wood et al. [30] took 1,346 clinical trial papers, which were subjects in 146 published meta-analyses, and divided them, based on the existence or non-existence of allocation concealment and post-allocation blinding, and then re-analyzed them. It was shown that when these items were not properly followed, the subjective evaluations of their effects were exaggerated. More recently, a trend of applying potential meta-confounders, such as genotype [52], study design [36,53], and the number of participants [54], can be seen.

Meta-meta-epidemiology and network meta-epidemiology

As seen in the aforementioned background of meta-epidemiology, if meta-epidemiology was developed to control diverse SR results, then the word “meta-meta-epidemiology” can be proposed for diverse results from meta-epidemiology [55].

Nonetheless, meta-epidemiology has a few limitations [47,55, 56]. First, the study results that allow analysis are dichotomous and cannot handle continuous outcomes; second, with the reduced number of journals as study subjects, statistical power is limited; and third, indirect comparisons cannot be applied. With the goal of overcoming these limitations, Chaimani et al. [47] proposed the term “network meta-epidemiology.” Concurrently, the term “mixed treatment comparison meta-analysis” was introduced to emphasize the point about making (in)direct comparisons when multiple intervention types are introduced [7,46]. To execute this, the development of research conducting tools [57,58], Copas parametric model [59,60], graphs presented [61], and published items [62], are currently under way.

For easily distinguishing the concepts of meta-meta-epidemiology and network meta-epidemiology, derived from meta-epidemiology as seen above, Trinquart et al. [55] presented a mutual comparison table.

CONCLUSIONS AND SUGGESTIONS

Valid SR results must be present to develop good clinical diagnostic guidelines, which would ultimately contribute to the improvement of overall healthcare. This is the background and aim of the meta-epidemiology emergence. To obtain valid SR results, the key challenge is to improve the quality of RCTs that are the subject of analysis by SR [36,63]. To this end, some suggestions are being made.

First, development and distribution of standardized quality assessment tools is needed to accurately assess the risk of error occurrence [64]. Cochrane Collaboration has proposed a tool called risk of bias [65-67]; more active meta-epidemiologic studies are needed using such tools to investigate what influences are imposed on SR reasoning [36].

Second, there is a need to more clearly organize the concepts behind the terminologies used in RCT quality assessment [68]. This is because concepts such as allocation concealment and post-allocation blinding must be revised and disseminated in a unified manner to researchers, as well as existing research methodology textbooks.

Third, in order to accurately verify and interpret the RCT study results in SRs, reports must be made without overlooking any of the designated items [35]. Since there are some reports indicating that following the reporting guideline in The Consolidated Standards for Reporting Trials (CONSORT) improves the quality of journals [69,70], RCT researches would need to obey this guideline.

Fourth, there is an international movement to have the study registered in an open venue prior to conducting the study to prevent overlooking study results, because cases of conflicting between initial plans and final results were surfaced [71]. As there is also the advantage of reducing publication bias [24], there is a need to accept this wholeheartedly in accordance with the international trend.

Acknowledgments

This study was supported by the 2014 scientific promotion program funded by Jeju National University.

Appendix 1. Examples of meta-epidemiologic studies

Meta-confounders References
Concealment & blindness A01
Placebo control vs. untreated control A02
Concealment & blindness A03
Genetic polymorphism A04
Exclusion of patients A05
Randomization & effect size A06
Single center vs. multicenter A07
Concealment A08
Experimental vs. observational design A09
Study design A10
Sample size A11

References

  • A01.Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336:601–605. doi: 10.1136/bmj.39465.451748.AD. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • A02.Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67:1716–1723. doi: 10.1136/ard.2008.092015. [DOI] [PubMed] [Google Scholar]
  • A03.Nüesch E, Reichenbach S, Trelle S, Rutjes AW, Liewald K, Sterchi R, et al. The importance of allocation concealment and patient blinding in osteoarthritis trials: a meta-epidemiologic study. Arthritis Rheum. 2009;61:1633–1641. doi: 10.1002/art.24894. [DOI] [PubMed] [Google Scholar]
  • A04.Valdes AM, Arden NK, Tamm A, Kisand K, Doherty S, Pola E, et al. A meta-analysis of interleukin-6 promoter polymorphisms on risk of hip and knee osteoarthritis. Osteoarthritis Cartilage. 2010;18:699–704. doi: 10.1016/j.joca.2009.12.012. [DOI] [PubMed] [Google Scholar]
  • A05.Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Bürgi E, Scherer M, et al. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ. 2009;339:e2014019. doi: 10.1136/bmj.b3244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • A06.Oliver S, Bagnall AM, Thomas J, Shepherd J, Sowden A, White I, et al. Randomised controlled trials for policy interventions: a review of reviews and meta-regression. Health Technol Assess. 2010;14:1–165. doi: 10.3310/hta14160. [DOI] [PubMed] [Google Scholar]
  • A07.Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann Intern Med. 2011;155:39–51. doi: 10.7326/0003-4819-155-1-201107050-00006. [DOI] [PubMed] [Google Scholar]
  • A08.Herbison P, Hay-Smith J, Gillespie WJ. Different methods of allocation to groups in randomized trials are associated with different levels of bias. A meta-epidemiological study. J Clin Epidemiol. 2011;64:1070–1075. doi: 10.1016/j.jclinepi.2010.12.018. [DOI] [PubMed] [Google Scholar]
  • A09.Tzoulaki I, Siontis KC, Ioannidis JP. Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ. 2011;343:e2014019. doi: 10.1136/bmj.d6829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • A10.Savović J, Jones H, Altman D, Harris R, Jűni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess. 2012;16:1–82. doi: 10.3310/hta16350. [DOI] [PubMed] [Google Scholar]
  • A11.Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ. 2013;346:e2014019. doi: 10.1136/bmj.f2304. [DOI] [PMC free article] [PubMed] [Google Scholar]

Footnotes

The author has no conflicts of interest to declare for this study.

SUPPLEMENTARY MATERIAL

Supplementary material is available at http://www.e-epih.org/.

REFERENCES

  • 1.Bae JM, Park BJ, Ahn YO. Perspectives of clinical epidemiology in Korea. J Korean Med Assoc. 2013;56:718–723. (Korean) [Google Scholar]
  • 2.Ioannidis JP, Schmid CH, Lau J. Meta-analysis in hematology and oncology. Hematol Oncol Clin North Am. 2000;14:973–991. doi: 10.1016/s0889-8588(05)70322-1. [DOI] [PubMed] [Google Scholar]
  • 3.Ahn HS, Kim HJ. An introduction to systematic review. J Korean Med Assoc. 2014;57:49–59. (Korean) [Google Scholar]
  • 4.Khoshdel A, Attia J, Carney SL. Basic concepts in meta-analysis: A primer for clinicians. Int J Clin Pract. 2006;60:1287–1294. doi: 10.1111/j.1742-1241.2006.01078.x. [DOI] [PubMed] [Google Scholar]
  • 5.Noble JH., Jr Meta-analysis: Methods, strengths, weaknesses, and political uses. J Lab Clin Med. 2006;147:7–20. doi: 10.1016/j.lab.2005.08.006. [DOI] [PubMed] [Google Scholar]
  • 6.Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–1737. doi: 10.1136/bmj.318.7200.1730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17:279–301. doi: 10.1177/0962280207080643. [DOI] [PubMed] [Google Scholar]
  • 8.Bae JM. An overview of systematic reviews of diagnostic tests accuracy. Epidemiol Health. 2014;36:e2014019. doi: 10.4178/epih/e2014016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Egger M, Smith GD, Sterne JA. Uses and abuses of meta-analysis. Clin Med. 2001;1:478–484. doi: 10.7861/clinmedicine.1-6-478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Stevens KR, Ledbetter CA. Basics of evidence-based practice. Part 1: The nature of the evidenc. Semin Perioper Nurs. 2000;9:91–97. [PubMed] [Google Scholar]
  • 11.Michels KB. Quo vadis meta-analysis? A potentially dangerous tool if used without adequate rules. Important Adv Oncol. 1992:243–248. [PubMed] [Google Scholar]
  • 12.Finckh A, Tramèr MR. Primer: strengths and weaknesses of meta-analysis. Nat Clin Pract Rheumatol. 2008;4:146–152. doi: 10.1038/ncprheum0732. [DOI] [PubMed] [Google Scholar]
  • 13.Morris RD. Meta-analysis in cancer epidemiology. Environ Health Perspect. 1994;102 Suppl 8:61–66. doi: 10.1289/ehp.94102s861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zhang W. Meta-epidemiology: building the bridge from research evidence to clinical practice. Osteoarthritis Cartilage. 2010;18 Suppl 2:S1. [Google Scholar]
  • 15.Robertson C, Idris NR, Boyle P. Beyond classical meta-analysis: can inadequately reported studies be included? Drug Discov Today. 2004;9:924–931. doi: 10.1016/S1359-6446(04)03274-X. [DOI] [PubMed] [Google Scholar]
  • 16.Sterne JA, Jüni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for assessing the influence of study characteristics on treatment effects in ‘meta-epidemiological’ research. Stat Med. 2002;21:1513–1524. doi: 10.1002/sim.1184. [DOI] [PubMed] [Google Scholar]
  • 17.Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet. 2001;358:1340–1342. doi: 10.1016/S0140-6736(01)06449-2. [DOI] [PubMed] [Google Scholar]
  • 18.Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412. doi: 10.1001/jama.273.5.408. [DOI] [PubMed] [Google Scholar]
  • 19.Gluud LL. Bias in clinical intervention research. Am J Epidemiol. 2006;163:493–501. doi: 10.1093/aje/kwj069. [DOI] [PubMed] [Google Scholar]
  • 20.Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14:951–957. doi: 10.1111/j.1365-2753.2008.00986.x. [DOI] [PubMed] [Google Scholar]
  • 21.Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012;41:818–827. doi: 10.1093/ije/dys041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009:e2014019. doi: 10.1002/14651858.MR000006.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Mahid SS, Qadan M, Hornung CA, Galandiuk S. Assessment of publication bias for the surgeon scientist. Br J Surg. 2008;95:943–949. doi: 10.1002/bjs.6302. [DOI] [PubMed] [Google Scholar]
  • 24.Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000;53:207–16. doi: 10.1016/s0895-4356(99)00161-4. [DOI] [PubMed] [Google Scholar]
  • 25.Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ. 2010;340:e2014019. doi: 10.1136/bmj.c365. [DOI] [PubMed] [Google Scholar]
  • 26.White IR, Welton NJ, Wood AM, Ades AE, Higgins JP. Allowing for uncertainty due to missing data in meta-analysis--part 2: hierarchical models. Stat Med. 2008;27:728–745. doi: 10.1002/sim.3007. [DOI] [PubMed] [Google Scholar]
  • 27.Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med. 2012;157:429–438. doi: 10.7326/0003-4819-157-6-201209180-00537. [DOI] [PubMed] [Google Scholar]
  • 28.Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001;323:42–46. doi: 10.1136/bmj.323.7303.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ. 2012;344:e2014019. doi: 10.1136/bmj.e1119. [DOI] [PubMed] [Google Scholar]
  • 30.Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336:601–605. doi: 10.1136/bmj.39465.451748.AD. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Bürgi E, Scherer M, et al. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ. 2009;339:e2014019. doi: 10.1136/bmj.b3244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Nüesch E, Reichenbach S, Trelle S, Rutjes AW, Liewald K, Sterchi R, et al. The importance of allocation concealment and patient blinding in osteoarthritis trials: a meta-epidemiologic study. Arthritis Rheum. 2009;61:1633–1641. doi: 10.1002/art.24894. [DOI] [PubMed] [Google Scholar]
  • 33.Siersma V, Als-Nielsen B, Chen W, Hilden J, Gluud LL, Gluud C. Multivariable modelling for meta-epidemiological assessment of the association between trial quality and treatment effects estimated in randomized clinical trials. Stat Med. 2007;26:2745–2758. doi: 10.1002/sim.2752. [DOI] [PubMed] [Google Scholar]
  • 34.Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH. In the dark: the reporting of blinding status in randomized controlled trials. J Clin Epidemiol. 2002;55:787–790. doi: 10.1016/s0895-4356(02)00446-8. [DOI] [PubMed] [Google Scholar]
  • 35.Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135:982–989. doi: 10.7326/0003-4819-135-11-200112040-00010. [DOI] [PubMed] [Google Scholar]
  • 36.Savović J, Jones H, Altman D, Harris R, Jűni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess. 2012;16:1–82. doi: 10.3310/hta16350. [DOI] [PubMed] [Google Scholar]
  • 37.Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609–613. doi: 10.1016/S0140-6736(98)01085-X. [DOI] [PubMed] [Google Scholar]
  • 38.Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA. 2002;287:2973–2982. doi: 10.1001/jama.287.22.2973. [DOI] [PubMed] [Google Scholar]
  • 39.Jackson R, Ameratunga S, Broad J, Connor J, Lethaby A, Robb G, et al. The GATE frame: critical appraisal with pictures. Evid Based Med. 2006;11:35–38. doi: 10.1136/ebm.11.2.35. [DOI] [PubMed] [Google Scholar]
  • 40.Altman DG, Schulz KF. Statistics notes: concealing treatment allocation in randomised trials. BMJ. 2001;323:446–447. doi: 10.1136/bmj.323.7310.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Pildal J, Chan AW, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ. 2005;330:1049. doi: 10.1136/bmj.38414.422650.8F. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Pildal J, Hróbjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol. 2007;36:847–857. doi: 10.1093/ije/dym087. [DOI] [PubMed] [Google Scholar]
  • 43.Schulz KF. Assessing allocation concealment and blinding in randomized controlled trials: why bother? ACP J Club. 2000;132:A11–A12. [PubMed] [Google Scholar]
  • 44.Hróbjartsson A, Pildal J, Chan AW, Haahr MT, Altman DG, Gøtzsche PC. Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. J Clin Epidemiol. 2009;62:967–973. doi: 10.1016/j.jclinepi.2009.04.003. [DOI] [PubMed] [Google Scholar]
  • 45.Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess. 2003;7:1–76. [PubMed] [Google Scholar]
  • 46.Salanti G, Dias S, Welton NJ, Ades AE, Golfinopoulos V, Kyrgiou M, et al. Evaluating novel agent effects in multiple-treatments meta-regression. Stat Med. 2010;29:2369–2383. doi: 10.1002/sim.4001. [DOI] [PubMed] [Google Scholar]
  • 47.Chaimani A, Vasiliadis HS, Pandis N, Schmid CH, Welton NJ, Salanti G. Effects of study precision and risk of bias in networks of interventions: a network meta-epidemiological study. Int J Epidemiol. 2013;42:1120–1131. doi: 10.1093/ije/dyt074. [DOI] [PubMed] [Google Scholar]
  • 48.Rücker G, Carpenter JR, Schwarzer G. Detecting and adjusting for small-study effects in meta-analysis. Biom J. 2011;53:351–368. doi: 10.1002/bimj.201000151. [DOI] [PubMed] [Google Scholar]
  • 49.Lyles RH, Allen AS, Dana Flanders W, Kupper LL, Christensen DL. Inference for case-control studies when exposure status is both informatively missing and misclassified. Stat Med. 2006;25:4065–4080. doi: 10.1002/sim.2500. [DOI] [PubMed] [Google Scholar]
  • 50.Naylor CD. Meta-analysis and the meta-epidemiology of clinical research. BMJ. 1997;315:617–619. doi: 10.1136/bmj.315.7109.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Le Lorier J, Grégoire G. Meta-analysis and the meta-epidemiology of clinical research. Comments on paper by author of editorial were unwarranted. BMJ. 1998;316:311–312. [PMC free article] [PubMed] [Google Scholar]
  • 52.Valdes AM, Arden NK, Tamm A, Kisand K, Doherty S, Pola E, et al. A meta-analysis of interleukin-6 promoter polymorphisms on risk of hip and knee osteoarthritis. Osteoarthritis Cartilage. 2010;18:699–704. doi: 10.1016/j.joca.2009.12.012. [DOI] [PubMed] [Google Scholar]
  • 53.Tzoulaki I, Siontis KC, Ioannidis JP. Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ. 2011;343:e2014019. doi: 10.1136/bmj.d6829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ. 2013;346:e2014019. doi: 10.1136/bmj.f2304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Trinquart L, Dechartres A, Ravaud P. Commentary: Meta-epidemiology, meta-meta-epidemiology or network meta-epidemiology? Int J Epidemiol. 2013;42:1131–1133. doi: 10.1093/ije/dyt137. [DOI] [PubMed] [Google Scholar]
  • 56.Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013;42:332–345. doi: 10.1093/ije/dys222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS One. 2014;9:e2014019. doi: 10.1371/journal.pone.0099682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Hutton B, Salanti G, Chaimani A, Caldwell DM, Schmid C, Thorlund K, et al. The quality of reporting methods and results in network meta-analyses: an overview of reviews and suggestions for improvement. PLoS One. 2014;9:e2014019. doi: 10.1371/journal.pone.0092508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Mavridis D, Sutton A, Cipriani A, Salanti G. A fully Bayesian application of the Copas selection model for publication bias extended to network meta-analysis. Stat Med. 2013;32:51–66. doi: 10.1002/sim.5494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Salanti G, Marinho V, Higgins JP. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol. 2009;62:857–864. doi: 10.1016/j.jclinepi.2008.10.001. [DOI] [PubMed] [Google Scholar]
  • 61.Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8:e2014019. doi: 10.1371/journal.pone.0076654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Bafeta A, Trinquart L, Seror R, Ravaud P. Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review. BMJ. 2013;347:e2014019. doi: 10.1136/bmj.f3675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.De Vito C, Manzoli L, Marzuillo C, Anastasi D, Boccia A, Villari P. A systematic review evaluating the potential for bias and the methodological quality of meta-analyses in vaccinology. Vaccine. 2007;25:8794–8806. doi: 10.1016/j.vaccine.2007.10.034. [DOI] [PubMed] [Google Scholar]
  • 64.Moja LP, Telaro E, D’Amico R, Moschetti I, Coe L, Liberati A. Assessment of methodological quality of primary studies by systematic reviews: results of the metaquality cross sectional study. BMJ. 2005;330:1053. doi: 10.1136/bmj.38414.515938.8F. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Hartling L, Ospina M, Liang Y, Dryden DM, Hooton N, Krebs Seida J, et al. Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. BMJ. 2009;339:e2014019. doi: 10.1136/bmj.b4012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:e2014019. doi: 10.1136/bmj.d5928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Schouten LM, Hulscher ME, van Everdingen JJ, Huijsman R, Grol RP. Evidence for the impact of quality improvement collaboratives: systematic review. BMJ. 2008;336:1491–1494. doi: 10.1136/bmj.39570.749884.BE. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA. 2001;285:2000–2003. doi: 10.1001/jama.285.15.2000. [DOI] [PubMed] [Google Scholar]
  • 69.Augestad KM, Berntsen G, Lassen K, Bellika JG, Wootton R, Lindsetmo RO, et al. Standards for reporting randomized controlled trials in medical informatics: a systematic review of CONSORT adherence in RCTs on clinical decision support. J Am Med Inform Assoc. 2012;19:13–21. doi: 10.1136/amiajnl-2011-000411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ. 2010;340:e2014019. doi: 10.1136/bmj.c723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Hill CL, LaValley MP, Felson DT. Discrepancy between published report and actual conduct of randomized clinical trials. J Clin Epidemiol. 2002;55:783–786. doi: 10.1016/s0895-4356(02)00440-7. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Epidemiology and Health are provided here courtesy of Korean Society of Epidemiology

RESOURCES